Arctigenin inhibits STAT3 and exhibits anticancer potential in human triple-negative breast cancer therapy

Oncotarget

Volumn 8, Issue 1, 2017, Pages 329-344

  Feng, Tingting ^a,b   Cao, Wei ^c   Shen, Wanxiang ^d   Zhang, Liang ^a   Gu, Xinsheng ^a   Guo, Yang ^a   Tsai, Hsiang i ^d   Liu, Xuewen ^a   Li, Jian ^a   Zhang, Jingxuan ^a   Li, Shan ^a   Wu, Fuyun ^a   Liu, Ying ^a  

^a HUBEI UNIVERSITY OF MEDICINE   (China)

^b ANHUI MEDICAL UNIVERSITY   (China)

^c TIANJIN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^d TSINGHUA UNIVERSITY   (China)

Author keywords

Arctigenin; Computational docking; STAT3; Taxotere; Triple negative breast cancers

Indexed keywords

ANTINEOPLASTIC AGENT; ARCTIGENIN; DNA; DOCETAXEL; FURAN DERIVATIVE; LIGNAN; STAT3 PROTEIN; STAT3 PROTEIN, HUMAN; TAXOID;

ANIMAL; APOPTOSIS; ARCTIUM; CELL PROLIFERATION; CHEMISTRY; DRUG EFFECT; DRUG POTENTIATION; DRUG SCREENING; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; HUMAN; HYDROGEN BOND; MEDICINAL PLANT; METABOLISM; MOLECULAR DOCKING; NUDE MOUSE; PATHOLOGY; PRECLINICAL STUDY; PROTEIN DOMAIN; SIGNAL TRANSDUCTION; TRIPLE NEGATIVE BREAST CANCER; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; ARCTIUM; ASIA, EASTERN; CELL LINE, TUMOR; CELL PROLIFERATION; DNA; DOCETAXEL; DRUG EVALUATION, PRECLINICAL; DRUG SYNERGISM; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; FURANS; HUMANS; HYDROGEN BONDING; LIGNANS; MICE, NUDE; MOLECULAR DOCKING SIMULATION; PLANTS, MEDICINAL; PROTEIN DOMAINS; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; TAXOIDS; TRIPLE NEGATIVE BREAST NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 85009471365     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.13393     Document Type: Article

References (47)

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. Cancer J Clin. 2015; 65:5-29.
2. Stevens KN, Vachon CM, Couch FJ. Genetic susceptibility to triple-negative breast cancer. Cancer Res. 2013; 73:2025-2030.
3. Deng XS, Wang S, Deng A, Liu B, Edgerton SM, Lind SE, Wahdan-Alaswad R, Thor AD. Metformin targets Stat3 to inhibit cell growth and induce apoptosis in triple-negative breast cancers. Cell Cycle. 2012; 11:367-376.
4. D'Amato NC, Rogers TJ, Gordon MA, Greene LI, Cochrane DR, Spoelstra NS, Nemkov TG, D'Alessandro A, Hansen KC, Richer JK. A TDO2-AhR Signaling Axis Facilitates Anoikis Resistance and Metastasis in Triple-Negative Breast Cancer. Cancer Res. 2015.
5. Goodwin CM, Rossanese OW, Olejniczak ET, Fesik SW. Myeloid cell leukemia-1 is an important apoptotic survival factor in triple-negative breast cancer. Cell Death Differ. 2015.
6. Cao W, Liu Y, Zhang R, Zhang B, Wang T, Zhu X, Mei L, Chen H, Zhang H, Ming P, Huang L. Homoharringtonine induces apoptosis and inhibits STAT3 via IL-6/JAK1/STAT3 signal pathway in Gefitinib-resistant lung cancer cells. SciRep. 2015; 5:8477.
7. Crescenzo R, Abate F, Lasorsa E, Tabbo' F, Gaudiano M, Chiesa N, Di GF, Spaccarotella E, Barbarossa L, Ercole E, Todaro M, Boi M, Acquaviva A, et al. Convergent mutations and kinase fusions lead to oncogenic STAT3 activation in anaplastic large cell lymphoma. Cancer Cell. 2015; 27:516-532.
8. Amin HM, McDonnell TJ, Ma Y, Lin Q, Fujio Y, Kunisada K, Leventaki V, Das P, Rassidakis GZ, Cutler C, Medeiros LJ, Lai R. Selective inhibition of STAT3 induces apoptosis and G(1) cell cycle arrest in ALK-positive anaplastic large cell lymphoma. Oncogene. 2004; 23:5426-5434.
9. Chun J, Li RJ, Cheng MS, Kim YS. Alantolactone selectively suppresses STAT3 activation and exhibits potent anticancer activity in MDA-MB-231 cells. Cancer Lett. 2015; 357:393-403.
10. Couto JP, Daly L, Almeida A, Knauf JA, Fagin JA, Sobrinho-Simoes M, Lima J, Maximo V, Soares P, Lyden D, Bromberg JF. STAT3 negatively regulates thyroid tumorigenesis. Proc Natl Acad Sci U S A. 2012; 109:E2361-2370.
11. Garcia R, Bowman TL, Niu G, Yu H, Minton S, Muro-Cacho CA, Cox CE, Falcone R, Fairclough R, Parsons S. Constitutive activation of Stat3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells. Oncogene. 2001; 20:2499-2513.
12. Fujita DJ, Ethier SP, Jove R. Constitutive Activation of Stat3 in Fibroblasts Transformed by Diverse Oncoproteins and in Breast Carcinoma Cells'. Cell Growth Differ. 1997; 8:12671276.
13. Pilati C, Amessou M, Bihl MP, Balabaud C, Van Nhieu JT, Paradis V, Nault JC, Izard T, Bioulac-Sage P, Couchy G. Somatic mutations activating STAT3 in human inflammatory hepatocellular adenomas. The Journal of experimental medicine. 2011; 208:1359-1366.
14. Zhang F, Li C, Halfter H, Liu J. Delineating an oncostatin M-activated STAT3 signaling pathway that coordinates the expression of genes involved in cell cycle regulation and extracellular matrix deposition of MCF-7 cells. Oncogene. 2003; 22:894-905.
15. Opdam FJ, Kamp M, de BR, Roos E. Jak kinase activity is required for lymphoma invasion and metastasis. Oncogene. 2004; 23:6647-6653.
16. Zhao X, Sun X, Li XL. Expression and clinical significance of STAT3, P-STAT3, and VEGF-C in small cell lung cancer. Asian PacJCancer Prev. 2012; 13:2873-2877.
17. Jiang R, Jin Z, Liu Z, Sun L, Wang L, Li K. Correlation of activated STAT3 expression with clinicopathologic features in lung adenocarcinoma and squamous cell carcinoma. MolDiagnTher. 2011; 15:347-352.
18. Venturutti L, Romero LV, Urtreger AJ, Chervo MF, Cordo Russo RI, Mercogliano MF, Inurrigarro G, Pereyra MG, Proietti CJ, Izzo F, Diaz Flaque MC, Sundblad V, Roa JC, et al. Stat3 regulates ErbB-2 expression and co-opts ErbB-2 nuclear function to induce miR-21 expression, PDCD4 downregulation and breast cancer metastasis. Oncogene. 2015.
19. Cho MK, Park JW, Jang YP, Kim YC, Kim SG. Potent inhibition of lipopolysaccharide-inducible nitric oxide synthase expression by dibenzylbutyrolactone lignans through inhibition of I-kappaBalpha phosphorylation and of p65 nuclear translocation in macrophages. IntImmunopharmacol. 2002; 2:105-116.
20. de Almeida AB, Sanchez-Hidalgo M, Martin AR, Luiz-Ferreira A, Trigo JR, Vilegas W, dos Santos LC, Souza-Brito AR and de la Lastra CA. Anti-inflammatory intestinal activity of Arctium lappa L. (Asteraceae) in TNBS colitis model. JEthnopharmacol. 2013; 146:300-310.
21. Lee YJ, Choi DH, Cho GH, Kim JS, Kang DG, Lee HS. Arctium lappa ameliorates endothelial dysfunction in rats fed with high fat/cholesterol diets. BMCComplement AlternMed. 2012; 12:116.
22. Yao X, Zhu F, Zhao Z, Liu C, Luo L, Yin Z. Arctigenin enhances chemosensitivity of cancer cells to cisplatin through inhibition of the STAT3 signaling pathway. JCell Biochem. 2011; 112:2837-2849.
23. Zhang X, Blaskovich MA, Forinash KD, Sebti SM. Withacnistin inhibits recruitment of STAT3 and STAT5 to growth factor and cytokine receptors and induces regression of breast tumours. BrJCancer. 2014; 111:894-902.
24. Sanchez-Lopez E, Flashner-Abramson E, Shalapour S, Zhong Z, Taniguchi K, Levitzki A, Karin M. Targeting colorectal cancer via its microenvironment by inhibiting IGF-1 receptor-insulin receptor substrate and STAT3 signaling. Oncogene. 2015.
25. Rebouissou S, Amessou M, Couchy G, Poussin K, Imbeaud S, Pilati C, Izard T, Balabaud C, Bioulac-Sage P, Zucman-Rossi J. Frequent in-frame somatic deletions activate gp130 in inflammatory hepatocellular tumours. Nature. 2009; 457:200-204.
26. Bachelot T, Ray-Coquard I, Menetrier-Caux C, Rastkha M, Duc A, Blay JY. Prognostic value of serum levels of interleukin 6 and of serum and plasma levels of vascular endothelial growth factor in hormone-refractory metastatic breast cancer patients. British journal of cancer. 2003; 88:1721-1726.
27. Hong DS, Angelo LS, Kurzrock R. Interleukin-6 and its receptor in cancer. Cancer. 2007; 110:1911-1928.
28. Zhong S, Yin H, Liao Y, Yao F, Li Q, Zhang J, Jiao H, Zhao Y, Xu D, Liu S, Song H, Gao Y, Liu J, et al. Lung Tumor Suppressor GPRC5A Binds EGFR, Restrains Its Effector Signaling. Cancer Res. 2015; 75:1801-1814.
29. Berclaz G, Altermatt HJ, Rohrbach V, Siragusa A, Dreher E, Smith PD. EGFR dependent expression of STAT3 (but not STAT1) in breast cancer. International journal of oncology. 2001; 19:1155-1160.
30. Gao SP, Mark KG, Leslie K, Pao W, Motoi N, Gerald WL, Travis WD, Bornmann W, Veach D, Clarkson B, Bromberg JF. Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas. The Journal of Clinical Investigation. 2007; 117:3846-3856.
31. Homeyer N, Horn AH, Lanig H, Sticht H. AMBER forcefield parameters for phosphorylated amino acids in different protonation states: phosphoserine, phosphothreonine, phosphotyrosine, and phosphohistidine. J Mol Model. 2006; 12:281-289.
32. Susanti S, Iwasaki H, Inafuku M, Taira N, Oku H. Mechanism of arctigenin-mediated specific cytotoxicity against human lung adenocarcinoma cell lines. Phytomedicine. 2013; 21:39-46.
33. Susanti S, Iwasaki H, Itokazu Y, Nago M, Taira N, Saitoh S, Oku H. Tumor specific cytotoxicity of arctigenin isolated from herbal plant Arctium lappa L. JNatMed. 2012; 66:614-621.
34. Hsieh CJ, Kuo PL, Hsu YC, Huang YF, Tsai EM, Hsu YL. Arctigenin, a dietary phytoestrogen, induces apoptosis of estrogen receptor-negative breast cancer cells through the ROS/p38 MAPK pathway and epigenetic regulation. Free RadicBiolMed. 2014; 67:159-170.
35. Ha K, Fiskus W, Choi DS, Bhaskara S, Cerchietti L, Devaraj SG, Shah B, Sharma S, Chang JC, Melnick AM, Hiebert S, Bhalla KN. Histone deacetylase inhibitor treatment induces 'BRCAness' and synergistic lethality with PARP inhibitor and cisplatin against human triple negative breast cancer cells. Oncotarget. 2014; 5:5637-50. doi: 10.18632/oncotarget.2154.
36. Frank DA. STAT3 as a central mediator of neoplastic cellular transformation. Cancer Lett. 2007; 251:199-210.
37. Gariboldi MB, Ravizza R, Molteni R, Osella D, Gabano E, Monti E. Inhibition of Stat3 increases doxorubicin sensitivity in a human metastatic breast cancer cell line. Cancer Lett. 2007; 258:181-188.
38. Lee Y, Jung WH, Koo JS. Adipocytes can induce epithelialmesenchymal transition in breast cancer cells. Breast cancer research and treatment. 2015; 153:323-335.
39. Azare J, Doane A, Leslie K, Chang Q, Berishaj M, Nnoli J, Mark K, Al-Ahmadie H, Gerald W, Hassimi M. Stat3 mediates expression of autotaxin in breast cancer. PLoS One. 2011; 6.
40. Thakur R, Trivedi R, Rastogi N, Singh M, Mishra DP. Inhibition of STAT3, FAK, Src mediated signaling reduces cancer stem cell load, tumorigenic potential and metastasis in breast cancer. Scientific reports. 2015; 5.
41. Kim SM, Kwon OJ, Hong YK, Kim JH, Solca F, Ha SJ, Soo RA, Christensen JG, Lee JH, Cho BC. Activation of IL-6R/JAK1/STAT3 Signaling Induces De Novo Resistance to Irreversible EGFR Inhibitors in Non-Small Cell Lung Cancer with T790M Resistance Mutation. Molecular Cancer Therapeutics. 2012; 11:2254-2264.
42. Liu Y, Li P-K, Li C, Lin J. Inhibition of STAT3 Signaling Blocks the Anti-apoptotic Activity of IL-6 in Human Liver Cancer Cells. Journal of Biological Chemistry. 2010; 285:27429-27439.
43. Fletcher S, Turkson J, Gunning PT. Molecular approaches towards the inhibition of the signal transducer and activator of transcription 3 (Stat3) protein. ChemMedChem. 2008; 3:1159-1168.
44. Liu Y, Cao W, Zhang B, Liu YQ, Wang ZY, Wu YP, Yu XJ, Zhang XD, Ming PH, Zhou GB, Huang L. The natural compound magnolol inhibits invasion and exhibits potential in human breast cancer therapy. SciRep. 2013; 3:3098.
45. Tatewaki H, Koga T, Shimazaki T, Yamamoto S. Quality of contracted Gaussian-type function basis sets. J Chem Phys. 2004; 120:5938-5945.
46. Durmaz V, Schmidt S, Sabri P, Piechotta C, Weber M. Hands-offlinear interaction energy approach to binding mode and affinity estimation of estrogens. J Chem Inf Model. 2013; 53:2681-2688.
47. Yildirim I, Kennedy SD, Stern HA, Hart JM, Kierzek R, Turner DH. Revision of AMBER Torsional Parameters for RNA Improves Free Energy Predictions for Tetramer Duplexes with GC and iGiC Base Pairs. J Chem Theory Comput. 2012; 8:172-181.